TET2 and hepatocellular carcinoma: As for TET2, the expression in HCC patients in the training set and the validation set was lower than that in the corresponding set of CHB patients, with statistical differences (training: t = 6.55, P < 0.001; validation: t = 5.36, P < 0.001).